Article

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion

2023-08-27

Abstract excerpt

Inhibition of CDK4/6 kinases has led to improved outcomes in breast cancer. Nevertheless, only a minority of patients experience long-term disease control. Using a clinically-annotated cohort of patients with metastatic HR+ breast cancer, we identified TP53 loss (28.8%) and MDM2 amplification (6.7%) to be associated with lack of long-term disease control. Human breast cancer models revealed that p53 loss did not...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 450bc048-f7d3-5e98-ad23-1a03439d31fb
DOI: 10.1101/2023.08.25.554716

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversionDOI 10.1101/2023.08.25.554716Read

Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalitiesSemantic proximity Read

Overexpression of Proteins Involved in Mitotic Progression Underlies High Proliferation and Chromosomal Instability in Androgen Receptor-Low Triple-Negative Breast CancerSemantic proximity Read

RB in Breast Cancer: The Crossroads of Tumorigenesis and TreatmentSemantic proximity Read

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancerSemantic proximity Read

Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsivenessSemantic proximity Read

Proteogenomic discovery of <i>RB1</i> -defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targetsSemantic proximity Read

Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancersSemantic proximity Read

TP53 mutation is associated with resistance to CDK4/6 Inhibitors, but not to Immune Checkpoint Inhibitors, in ER-positive/HER2-negative Breast Cancer: Real-World perspectiveSemantic proximity Read

Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness.Semantic proximity Read

Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.Semantic proximity Read

Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast CancerSemantic proximity Read

TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective.Semantic proximity Read